Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Rasche, Leo [VerfasserIn]   i
 Kortüm, K. Martin [VerfasserIn]   i
 Raab, Marc-Steffen [VerfasserIn]   i
 Weinhold, Niels [VerfasserIn]   i
Titel:The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma
Verf.angabe:Leo Rasche, K. Martin Kortüm, Marc S. Raab and Niels Weinhold
E-Jahr:2019
Jahr:12 March 2019
Umfang:14 S.
Illustrationen:Illustrationen
Fussnoten:Gesehen am 07.06.2019
Titel Quelle:Enthalten in: International journal of molecular sciences
Ort Quelle:Basel : Molecular Diversity Preservation International, 2000
Jahr Quelle:2019
Band/Heft Quelle:20 (2019,5) Artikel-Nummer 1248, Seite 1-14, 14 Seiten
ISSN Quelle:1422-0067
 1661-6596
Abstract:Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple different initiating events. A recent multi-region sequencing study demonstrated spatial differences, with progression events, such as TP53 mutations, frequently being restricted to focal lesions. In this review article, we describe the clinical impact of these two types of tumor heterogeneity. Target mutations are often dominant at one site but absent at other sites, which poses a significant challenge to personalized therapy in myeloma. The same holds true for high-risk subclones, which can be locally restricted, and as such not detectable at the iliac crest, which is the usual sampling site. Imaging can improve current risk classifiers and monitoring of residual disease, but does not allow for deciphering the molecular characteristics of tumor clones. In the era of novel immunotherapies, the clinical impact of heterogeneity certainly needs to be re-defined. Yet, preliminary observations indicate an ongoing impact of spatial heterogeneity on the efficacy of monoclonal antibodies. In conclusion, we recommend combining molecular tests with imaging to improve risk prediction and monitoring of residual disease. Overcoming intra-tumor heterogeneity is the prerequisite for curing myeloma. Novel immunotherapies are promising but research addressing their impact on the spatial clonal architecture is highly warranted.
DOI:doi:10.3390/ijms20051248
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/ijms20051248
 Volltext: https://www.mdpi.com/1422-0067/20/5/1248
 DOI: https://doi.org/10.3390/ijms20051248
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:clinical imaging
 daratumumab
 immunotherapy
 minimal residual disease
 multiple myeloma
 risk stratification
 spatial heterogeneity
 targeted therapy
K10plus-PPN:1666997196
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68397257   QR-Code
zum Seitenanfang